Increase In Deaths Linked To First Line Treatment With Sulfonylureas Reply

First-line treatment with sulfonylureas instead of metformin in people with type 2 diabetes is associated with a significantly elevated risk of death, according to results from an observational study presented at the European Association for the Study of Diabetes (EASD) meeting in Barcelona.

Although guidelines do not recommend the use of sulfonylureas for first-line treatment, the drugs are still commonly prescribed this way in many countries. CJ Currie, an epidemiologist at Cardiff University in the UK, said that 7% of diabetics in the United Kingdom receive first-line treatment with sulfonylureas. He presented data from the Clinical Practice Research Datalink (CPRD), which includes 10% of primary care patients in the United Kingdom. Between 2000 and 2012, 76,811 patients with type 2 diabetes began glucose-lowering treatment with metformin, while 15,687 began treatment with sulfonylureas (which include glipizide, glyburide, and glimepiride).

After adjusting for baseline differences, mortality was 58% higher in the sulfonylurea group….

Click here to read the full story on Forbes.

 

 

Advertisements

Top Line Results: No Cardiovascular Benefits Found For Saxagliptin Reply

Top line results of a large phase 4 study with saxagliptin (Onglyza, Bristol-Myers Squibb and AstraZeneca) demonstrate that the drug is safe but has no cardiovascular benefits. AstraZeneca and Bristol-Myers Squibb today announced the top line results for the SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza®. The full results are scheduled to presented at the  annual meeting of the European Society of Cardiology in Amsterdam on September 2 by Deepak Bhatt.

Click here to read the full story on Forbes.